# A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

> **NCT04825678** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 240 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Erenumab

## Key facts

- **NCT ID:** NCT04825678
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-11
- **Primary completion:** 2023-09-28
- **Final completion:** 2023-09-28
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04825678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04825678, "A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04825678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*